{"id":"CHEMBL1029","canonicalSmiles":"CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO","inchiKey":"UQRORFVVSGFNRO-UTINFBMNSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"MIGLUSTAT","yearOfFirstApproval":2003,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Zavesca"],"synonyms":["Butyldeoxynojirimycin","Miglustat","N-butyldeoxynojirimycin","OGT 918","OGT-918"],"crossReferences":{"DailyMed":["miglustat"],"PubChem":["144204381","170464950"],"Wikipedia":["Miglustat"],"drugbank":["DB00419"],"chEBI":["50381"]},"childChemblIds":["CHEMBL1329690"],"linkedTargets":{"rows":["ENSG00000148154"],"count":1},"linkedDiseases":{"rows":["Orphanet_77259","Orphanet_646","Orphanet_365","Orphanet_796","EFO_0000764","Orphanet_309152","Orphanet_79264","Orphanet_586","Orphanet_355","Orphanet_685","Orphanet_79201"],"count":11},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and is indicated for gaucher disease and gaucher disease type 1 and has 8 investigational indications."}
{"id":"CHEMBL1045","canonicalSmiles":"O=C(O)c1ccccc1C(=O)O","inchiKey":"XNGIFLGASWRNHJ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PHTHALIC ACID","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Phthalic acid"],"crossReferences":{"PubChem":["144208113","17389679","56436658"],"drugbank":["DB02746"],"chEBI":["29069"]},"childChemblIds":["CHEMBL3187152"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL108483","canonicalSmiles":"N#Cc1ccc(N(Cc2ccc(OS(N)(=O)=O)c(Br)c2)n2cnnc2)cc1","inchiKey":"GHDKYBCUDPSXGJ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL108483","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB04600"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1096896","canonicalSmiles":"CCNC(=O)[C@H]1O[C@@H](n2cnc3c(NCC(c4ccccc4)c4ccccc4)nc(C(=O)NCCNC(=O)NC4CCN(c5ccccn5)CC4)nc32)[C@H](O)[C@@H]1O","inchiKey":"ZOTHAEBAWXWVID-HXEFRTELSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"UK432097","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Uk432097"],"crossReferences":{"drugbank":["DB12691"]},"linkedTargets":{"rows":["ENSG00000128271"],"count":1},"linkedDiseases":{"rows":["EFO_0000341"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL1104","canonicalSmiles":"CC[N+](C)(C)c1cccc(O)c1","inchiKey":"VWLHWLSRQJQWRG-UHFFFAOYSA-O","drugType":"Small molecule","blackBoxWarning":false,"name":"EDROPHONIUM","yearOfFirstApproval":1951,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["ENLON-PLUS","Edrophonium","Edrophonium cation","Edrophonium ion","Enlon","Reversol","Tensilon"],"crossReferences":{"PubChem":["11111143","11111144","50100235","50104222","90341680"],"drugbank":["DB01010"],"chEBI":["251408"]},"childChemblIds":["CHEMBL60745","CHEMBL1128"],"linkedTargets":{"rows":["ENSG00000087085"],"count":1},"linkedDiseases":{"rows":["Orphanet_230","EFO_1000645","EFO_0005252"],"count":3},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1951 and has 2 investigational indications."}
{"id":"CHEMBL1144","canonicalSmiles":"CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@H]21","inchiKey":"TUZYXOIXSAXUGO-PZAWKZKUSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PRAVASTATIN","yearOfFirstApproval":1991,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["C10AA03","Pravachol","Pravastatin","Pravator"],"crossReferences":{"DailyMed":["pravastatin%20sodium"],"Wikipedia":["Pravastatin"],"drugbank":["DB00175"],"chEBI":["63618"]},"childChemblIds":["CHEMBL690"],"linkedTargets":{"rows":["ENSG00000113161"],"count":1},"linkedDiseases":{"rows":["MONDO_0005090","MONDO_0007254","EFO_1000727","EFO_0003913","EFO_0000565","EFO_0003914","EFO_0004246","EFO_0002690","EFO_1001375","EFO_0003144","MONDO_0008903","EFO_0003884","MONDO_0020732","EFO_0004255","EFO_0006890","EFO_0000182","EFO_0000400","EFO_0004705","EFO_0000685","HP_0002140","HP_0003124","HP_0001919","EFO_0001645","EFO_0000180","Orphanet_3389","EFO_0003929","EFO_0000319","EFO_0000313","Orphanet_740","EFO_1001496","EFO_0004911","Orphanet_309005","EFO_0000537","EFO_0003106","MONDO_0002691","MONDO_0021187","MONDO_0021661","EFO_1000049","EFO_0000764","Orphanet_79211","MONDO_0005147","Orphanet_412","EFO_0003854","EFO_0008583","EFO_0000574","EFO_0000612","EFO_1001121","EFO_0003918","EFO_0005411","EFO_0000668","EFO_0005672","MONDO_0005148"],"count":52},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 10 approved and 38 investigational indications."}
{"id":"CHEMBL1160695","canonicalSmiles":"CN[C@@H](C)[C@H](O)c1ccc(O)cc1","inchiKey":"OXFGTKPPFSCSMA-XVKPBYJWSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1160695","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB11610"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1200330","canonicalSmiles":"CC[C@@H]1C(=O)OC[C@@H]1Cc1cncn1C.Cl","inchiKey":"RNAICSBVACLLGM-GNAZCLTHSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PILOCARPINE HYDROCHLORIDE","yearOfFirstApproval":1984,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL550","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Isopto carpine","Ocusert","Piloc hcl","Pilocarpine hydrochloride","Pilogel","Pilopine","Pilopine hs","Salagen","Sno pilo"],"synonyms":["Pilocarpine hcl","Pilocarpine hydrochloride","Pilocarpine monohydrochloride","Pilocarpini hydrochloridum","Pilocarpinum muriaticum","Salagen","Vistacarpin n"],"crossReferences":{"DailyMed":["pilocarpine%20hydrochloride"],"PubChem":["26719685","50106827","539062","855931"]},"linkedTargets":{"rows":["ENSG00000133019","ENSG00000168539"],"count":2},"linkedDiseases":{"rows":["MONDO_0001330","EFO_0006859","EFO_1001914"],"count":3},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1984 and has 1 investigational indication."}
{"id":"CHEMBL1200698","drugType":"Small molecule","blackBoxWarning":false,"name":"PENTETATE CALCIUM TRISODIUM YB 169","yearOfFirstApproval":1976,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL2110560","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Ytterbium yb 169 dtpa"],"synonyms":["169yb","COMPOUND 24266","MATERIAL A","MATERIAL-A","MRP-10","Pentetate calcium trisodium yb 169","Pentetate calcium trisodium yb-169","Ytterbium yb-169 dtpa"],"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1976."}
{"id":"CHEMBL1200747","canonicalSmiles":"CC(O)C(=O)O.N","inchiKey":"RZOBLYBZQXQGFY-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"AMMONIUM LACTATE","yearOfFirstApproval":1985,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Ammonium lactate","Lac-hydrin"],"synonyms":["Ammonium lactate","BMS-186091","E328","Lac hydrin","NSC-760427"],"crossReferences":{"DailyMed":["ammonium%20lactate"],"DrugCentral":["4476"],"Wikipedia":["Ammonium_lactate"],"drugbank":["DB06768"]},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1985."}
{"id":"CHEMBL1200869","canonicalSmiles":"Cc1ncc([N+](=O)[O-])n1CCO.Cl","inchiKey":"FPTPAIQTXYFGJC-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"METRONIDAZOLE HYDROCHLORIDE","yearOfFirstApproval":1980,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL137","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Flagyl","Flagyl i.v.","Metronidazole hydrochloride"],"synonyms":["Metronidazole hcl","Metronidazole hydrochloride","SC-32642"],"crossReferences":{"chEBI":["50687"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1980 and has 3 investigational indications."}
{"id":"CHEMBL1201071","canonicalSmiles":"CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@@](C)(O)[C@H]3C[C@@H]12.O=P(O)(O)O","inchiKey":"WXDJNRXQVCECPF-FMZCEJRJSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TETRACYCLINE PHOSPHATE COMPLEX","yearOfFirstApproval":1957,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1440","hasBeenWithdrawn":true,"isApproved":true,"withdrawnNotice":{"countries":["United States"]},"tradeNames":["Tetrex"],"synonyms":["Tetracycline hexametaphosphate","Tetracycline metaphosphate","Tetracycline phosphate complex"],"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1957. It was withdrawn in United States."}
{"id":"CHEMBL1201190","canonicalSmiles":"Cl.Cl.O=C(O)COCCN1CCN([C@H](c2ccccc2)c2ccc(Cl)cc2)CC1","inchiKey":"PGLIUCLTXOYQMV-GHVWMZMZSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"LEVOCETIRIZINE DIHYDROCHLORIDE","yearOfFirstApproval":2007,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1201191","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Levocetirizine dihydrochloride","Xusal","Xyzal","Xyzal allergy 24hr","Xyzall"],"synonyms":["Cetirizine (r)-form dihydrochloride","Levocetirizine dihydrochloride","Levocetirizine hydrochloride","NSC-758898","UCB 28556","UCB-28556"],"crossReferences":{"DailyMed":["levocetirizine%20dihydrochloride"]},"linkedTargets":{"rows":["ENSG00000196639"],"count":1},"linkedDiseases":{"rows":["EFO_0008521","EFO_0005531","HP_0000989","Orphanet_79292","HP_0012735","EFO_0007141","EFO_1001417","MONDO_0004784","EFO_0003956"],"count":9},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and has 5 approved and 3 investigational indications."}
{"id":"CHEMBL1201263","canonicalSmiles":"CCN(CC)CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C","inchiKey":"FWFVLWGEFDIZMJ-FOMYWIRZSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"HYDROCORTAMATE","yearOfFirstApproval":1956,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Hydrocortamate"],"crossReferences":{"PubChem":["170465314"],"drugbank":["DB00769"],"chEBI":["50851"]},"childChemblIds":["CHEMBL1200635"],"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1956."}
{"id":"CHEMBL1201279","canonicalSmiles":"[Zn]","inchiKey":"HCHKCACWOHOZIP-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1201279","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB01593"],"chEBI":["30185"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1201466","drugType":"Small molecule","blackBoxWarning":true,"name":"ESTROGENS, CONJUGATED SYNTHETIC A","yearOfFirstApproval":1999,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Cenestin","Synthetic conjugated estrogens a"],"synonyms":["Estrogens, conjugated synthetic a","Estrogens,conjugated synthetic a"],"crossReferences":{"DailyMed":["estrogens,%20conjugated%20synthetic%20a"]},"linkedTargets":{"rows":["ENSG00000091831","ENSG00000140009"],"count":2},"linkedDiseases":{"rows":["EFO_1000096","EFO_0003922"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and is indicated for atrophy and menopause. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1201469","drugType":"Small molecule","blackBoxWarning":false,"name":"GRAMICIDIN","yearOfFirstApproval":1968,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Gramoderm"],"synonyms":["Gramicidin","Gramicidin d","Gramicidins","NSC-757043"],"crossReferences":{"DailyMed":["gramicidin"],"DrugCentral":["4794"]},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1968 and has 1 investigational indication."}
{"id":"CHEMBL1201550","drugType":"Protein","blackBoxWarning":true,"name":"DENILEUKIN DIFTITOX","yearOfFirstApproval":1999,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Ontak"],"synonyms":["DAB(SUB 389)IL2","DAB-389IL2","DAB389 IL2","DAB389IL2","Denileukin","Denileukin diftitox","E-7272","E-7777","E7272","E7777","LY-335348","LY335348"],"crossReferences":{"DrugCentral":["5087"],"Wikipedia":["Denileukin_diftitox","Resimmune"]},"linkedTargets":{"rows":["ENSG00000167658","ENSG00000134460","ENSG00000100385"],"count":3},"linkedDiseases":{"rows":["MONDO_0013730","EFO_0002618","EFO_0000616","EFO_0011061","EFO_0000466","EFO_0000756","MONDO_0008170","EFO_0002913","EFO_0000222","MONDO_0004222","EFO_0000209","EFO_0005952","MONDO_0002087","EFO_0000211","EFO_0000565","MONDO_0002158","EFO_1000043","EFO_0006861","EFO_0000095","EFO_1000251","EFO_0000574","MONDO_0002367","EFO_1001051","EFO_0001378","EFO_1000785","EFO_1001963"],"count":26},"description":"Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and is indicated for cutaneous t-cell lymphoma and neoplasm and has 19 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1201605","drugType":"Antibody","blackBoxWarning":false,"name":"DACLIZUMAB","yearOfFirstApproval":1997,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Zenapax","Zinbryta"],"synonyms":["Daclizumab","Daclizumab beta","RO 24-7375","RO-24-7375"],"crossReferences":{"DrugCentral":["4953"],"Wikipedia":["Daclizumab"]},"linkedTargets":{"rows":["ENSG00000134460"],"count":1},"linkedDiseases":{"rows":["EFO_0000729","EFO_0003086","EFO_0004683","MONDO_0019471","EFO_0000756","MONDO_0019541","HP_0001915","EFO_0000540","EFO_1002048","EFO_0000565","EFO_0003884","EFO_0000676","EFO_0000183","EFO_0000400","EFO_0000198","MONDO_0013730","EFO_0000616","EFO_0003929","HP_0001873","EFO_0004599","MONDO_0001705","Orphanet_567","EFO_1001231","MONDO_0005301","EFO_0005297","EFO_0000764","MONDO_0005147","EFO_0000574","MONDO_0004979","EFO_0001378","HP_0012410"],"count":31},"description":"Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for immune system disease and relapsing-remitting multiple sclerosis and has 24 investigational indications."}
{"id":"CHEMBL1201621","drugType":"Protein","blackBoxWarning":false,"name":"SOMATROPIN","yearOfFirstApproval":1976,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Accretropin","Asellacrin 10","Asellacrin 2","Bio-tropin","Crescormon","Genotropin","Genotropin [Rdna Origin]","Genotropin goquick","Genotropin kabipen","Genotropin kabiquick","Genotropin kabivial","Genotropin miniquick","Genotropin preservative free","Humatrope","Humatropen","Norditropin","Norditropin flexpro","Norditropin nordiflex","Norditropin penset","Norditropin simplexx","Nutropin","Nutropin aq","Nutropin aq nuspin","Nutropin aq pen","Nutropin depot","Nutropinaq","Omnitrope","Omnitrope pen 10","Omnitrope pen 5","Omnitrope surepal 10","Omnitrope surepal 15","Omnitrope surepal 5","Saizen","Saizen click.easy","Saizen easyject","Serostim","Serostim lq","Tev-Tropin","Valtropin","Zomacton","Zorbtive"],"synonyms":["CB-311","DA-3002","Genotonorm","Growth hormone","Growth hormone (human)","Hsb-hgh","Human growth hormone","Hypertropin","LY-137998","LY137998","R-hgh","Recombinant human growth hormone","Rh-polypeptide-7","Somatotropin","Somatotropin (human)","Somatotropin human","Somatotropin human growth hormone","Somatropin","Somatropin (rdna origin)","Somatropin biopartners","Somatropin for injection","Somatropin recombinant","Tev-tropin","Tevtropin","Vexxon-hgh"],"crossReferences":{"DailyMed":["somatropin","somatropin%20recombinant"],"DrugCentral":["4848"]},"linkedTargets":{"rows":["ENSG00000112964"],"count":1},"linkedDiseases":{"rows":["EFO_0008525","EFO_0005687","EFO_1001919","Orphanet_429","Orphanet_586","EFO_0001379","EFO_0000495","EFO_1000727","EFO_0002950","EFO_0007312","HP_0100543","EFO_1000653","Orphanet_739","EFO_0009607","EFO_0003144","EFO_0003884","HP_0001518","MONDO_0015183","EFO_0004616","Orphanet_583","MONDO_0004976","EFO_1002012","EFO_0000400","MONDO_0001967","EFO_0004705","EFO_0001380","EFO_0003888","Orphanet_79443","Orphanet_48652","Orphanet_648","EFO_0000545","EFO_0008560","EFO_0000180","HP_0001507","Orphanet_269","EFO_1001109","EFO_0009516","EFO_0000319","Orphanet_666","EFO_0001073","EFO_0000384","Orphanet_365563","EFO_0000195","HP_0004322","EFO_0001422","GO_0007568","MONDO_0100096","EFO_1001999","EFO_0000764","HP_0004326","Orphanet_881","MONDO_0043510","MONDO_0015514","HP_0001510","EFO_0003944","EFO_1001434"],"count":56},"description":"Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1976 and has 14 approved and 29 investigational indications."}
{"id":"CHEMBL1201646","drugType":"Unknown","blackBoxWarning":false,"name":"INULIN","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Inulin and sodium chloride"],"synonyms":["Chicory root inulin","Inulin"],"crossReferences":{"DrugCentral":["1447"],"Wikipedia":["Inulin"]},"description":"Unknown drug with a maximum clinical trial phase of IV (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL1201649","drugType":"Small molecule","blackBoxWarning":true,"name":"ESTROGENS, CONJUGATED","yearOfFirstApproval":1942,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Cenestin","Oestrogen","Premarin","Premarin Cream"],"synonyms":["Conjugated estrogens","Estrogen, conjugated (class)","Estrogens conjugated","Estrogens, conjugated","Estrogens,conjugated","G03CA57","Oestrogens conjugated"],"crossReferences":{"DailyMed":["estrogens,%20conjugated"],"DrugCentral":["4855"]},"linkedTargets":{"rows":["ENSG00000091831","ENSG00000140009"],"count":2},"linkedDiseases":{"rows":["EFO_0003869","EFO_1001864","MONDO_0001410","MONDO_0007254","HP_0031217","EFO_0003882","EFO_1001271","HP_0000938","EFO_0003103","MONDO_0041161","HP_0002907","MONDO_0002146","EFO_0004714","EFO_1001375","EFO_0002690","EFO_0004266","MONDO_0005180","EFO_0000712","EFO_1000096","EFO_0000400","EFO_0004215","EFO_0004288","EFO_0000545","HP_0003124","EFO_0002687","EFO_0001645","EFO_0001073","MONDO_0008315","HP_0030016","EFO_0001663","EFO_0000537","EFO_0001072","EFO_1000985","EFO_0003854","MONDO_0000831","MONDO_0011962","MONDO_0004975","EFO_1000781","EFO_0000612","Orphanet_881","MONDO_0043510","HP_0031273","EFO_0003922"],"count":43},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1942 and has 10 approved and 25 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1201670","drugType":"Protein","blackBoxWarning":false,"name":"SARGRAMOSTIM","yearOfFirstApproval":1991,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Leukine"],"synonyms":["B1 61.012","B1-61012","Granulocyte-macrophage colony-stimulating factor sargramostim","RHU GM-CSF","RHU-GM-CSF","Sargramostim","Sargramostim rdna"],"crossReferences":{"DailyMed":["sargramostim"],"DrugCentral":["5025"],"Wikipedia":["Sargramostim"]},"linkedTargets":{"rows":["ENSG00000198223"],"count":1},"linkedDiseases":{"rows":["EFO_1000403","EFO_0000637","EFO_0011061","MONDO_0100130","EFO_0003891","EFO_0000756","EFO_0000681","EFO_0005952","EFO_1000984","EFO_1001951","MONDO_0000548","EFO_0000339","MONDO_0008903","EFO_1000251","EFO_0005046","EFO_0002918","EFO_0004991","MONDO_0024885","EFO_0000198","EFO_0002618","MONDO_0013730","EFO_0000180","MONDO_0004986","EFO_0000384","MONDO_0008315","EFO_0001663","EFO_0000546","MONDO_0002691","MONDO_0000544","EFO_0000574","EFO_0001378","EFO_1000125","EFO_1000142","EFO_0003086","EFO_1001465","MONDO_0007254","MONDO_0001056","MONDO_0002158","MONDO_0005180","EFO_0000183","EFO_0003921","EFO_0000616","EFO_0000694","EFO_0000403","EFO_1001042","MONDO_0007576","EFO_0000222","EFO_0000304","EFO_1000097","EFO_0000649","EFO_0000764","MONDO_0011962","EFO_0000199","MONDO_0002367","MONDO_0018906","MONDO_0024880","EFO_0000519","EFO_0004265","EFO_0003869","EFO_0001075","MONDO_0000956","EFO_1000657","MONDO_0004222","EFO_0000228","EFO_0000565","EFO_0000309","EFO_0000544","HP_0001871","EFO_0000389","EFO_1001302","EFO_0000182","MONDO_0005411","EFO_0003893","EFO_0000466","EFO_0000220","MONDO_0021321","MONDO_0008170","EFO_0005842","EFO_0000502","MONDO_0044881","EFO_0004239","EFO_0009708","HP_0100806","MONDO_0100096","EFO_0005537","EFO_0002428","EFO_1000130","EFO_0000432","EFO_0006544","MONDO_0100342","MONDO_0015686","EFO_1001469","MONDO_0021063","MONDO_0002087","EFO_0000305","EFO_1000357","MONDO_0001187","EFO_1001480","EFO_1000044","EFO_1000043","Orphanet_264675","MONDO_0001475","EFO_0000673","MONDO_0001437","EFO_1001963","EFO_0002617","EFO_1000158","MONDO_0015667","EFO_0000685","EFO_1000616","EFO_0000545","HP_0001945","EFO_0000313","EFO_0000621","EFO_0003060","EFO_0000311","EFO_0006861","EFO_0000095","EFO_0006475","MONDO_0004975","EFO_0004142","MONDO_0020077","EFO_0003833","EFO_0000691","EFO_0000181","EFO_0003811"],"count":126},"description":"Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and is indicated for acute myeloid leukemia and acute myeloid leukemia by fab classification and has 96 investigational indications."}
{"id":"CHEMBL1205","canonicalSmiles":"CS(=O)(=O)O.Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C","inchiKey":"NQHXCOAXSHGTIA-SKXNDZRYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"NELFINAVIR MESYLATE","yearOfFirstApproval":1997,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL584","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Viracept"],"synonyms":["AG-1343","AG1343","Nelfinavir mesilate","Nelfinavir mesylate","Nelfinavir methanesulfonate","Nelfinaviri mesilas"],"crossReferences":{"DailyMed":["nelfinavir%20mesylate"],"PubChem":["144204572","144208119","170465351","17388868","49681600"],"chEBI":["7497"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for hiv-1 infection and hiv infection and has 8 investigational indications."}
{"id":"CHEMBL1207358","canonicalSmiles":"O=C(O)c1cc(=O)[nH]c(=O)n1[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]1O","inchiKey":"KYOBSHFOBAOFBF-XVFCMESISA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"OROTIDINE MONOPHOSPHATE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Orotidine Monophosphate"],"crossReferences":{"drugbank":["DB02957"],"chEBI":["15842"]},"childChemblIds":["CHEMBL1627081"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1231501","canonicalSmiles":"C[C@H](O)CCO","inchiKey":"PUPZLCDOIYMWBV-BYPYZUCNSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"1,3-BUTANEDIOL","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB02202"],"chEBI":["52688"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1231909","canonicalSmiles":"O=C(NCCCc1ccccc1)NC1CCCCC1","inchiKey":"HBTZVNKXMFGOOJ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1231909","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB04213"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1232448","canonicalSmiles":"O=C[C@H](O)[C@H](O)COP(=O)(O)O","inchiKey":"NGHMDNPXVRFFGS-IUYQGCFVSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"D-Erythrose 4-Phosphate","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["D-Erythrose 4-Phosphate"],"crossReferences":{"drugbank":["DB03937"],"chEBI":["48153"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1237124","canonicalSmiles":"C=C1c2c(Cl)ccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@H]12","inchiKey":"GGQJXCQBBONZFX-IWVLMIASSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"MECLOCYCLINE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["GS-2989","Meclocycline","NSC-78502"],"crossReferences":{"Wikipedia":["Meclocycline"],"drugbank":["DB13092"]},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL1256391","canonicalSmiles":"Cc1ccc(=O)n(-c2ccccc2)c1","inchiKey":"ISWRGOKTTBVCFA-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PIRFENIDONE","yearOfFirstApproval":2011,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Esbriet"],"synonyms":["AMR-69","NSC-748456","Pirespa","Pirfenidone"],"crossReferences":{"DailyMed":["pirfenidone"],"PubChem":["11113908","144203776","170465606","46500438","50104718","85231182","90341749"],"Wikipedia":["Pirfenidone"],"drugbank":["DB04951"],"chEBI":["32016"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and is indicated for immune system disease and idiopathic pulmonary fibrosis and has 24 investigational indications."}
{"id":"CHEMBL126075","canonicalSmiles":"COc1cc(C(=O)OCCCN2CCCN(CCCOC(=O)c3cc(OC)c(OC)c(OC)c3)CC2)cc(OC)c1OC","inchiKey":"QVZCXCJXTMIDME-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DILAZEP","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Dilazep","Dilazep dihydrochloride"],"crossReferences":{"PubChem":["104171321","11111074","11112657","11113524","124882501","144204139","170465831","26751736","50111024","90340761"],"Wikipedia":["Dilazep"],"drugbank":["DB13715"]},"childChemblIds":["CHEMBL1256327","CHEMBL1603820"],"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL127592","canonicalSmiles":"CN(C(=O)CN(CCO)CC(=O)N(C)C(C)(C)Cc1ccccc1)C(C)(C)Cc1ccccc1","inchiKey":"FTLDJPRFCGDUFH-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"OXETHAZAINE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["NSC-758444","Oxetacaine","Oxethazaine","Strocain","WY-806"],"crossReferences":{"PubChem":["11112275","124882156","144203958","170465643","26748773","56463559"],"Wikipedia":["Oxetacaine"],"drugbank":["DB12532"],"chEBI":["31947"]},"description":"Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL1371770","canonicalSmiles":"c1cnc(N2CCN(Cc3ccc4c(c3)OCO4)CC2)nc1","inchiKey":"OQDPVLVUJFGPGQ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PIRIBEDIL","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Trivastal","Trivastal lp"],"synonyms":["ET-495","EU-4200","Piribedil"],"crossReferences":{"PubChem":["104171222","11111687","11111688","11113867","144203796","170466242","90341513"],"Wikipedia":["Piribedil"],"drugbank":["DB12478"]},"childChemblIds":["CHEMBL4594075","CHEMBL1865834","CHEMBL1256997","CHEMBL1468572"],"description":"Small molecule drug with a maximum clinical trial phase of IV and is indicated for parkinson disease."}
{"id":"CHEMBL1401","canonicalSmiles":"CC(=O)Oc1ccccc1C(=O)Nc1ncc([N+](=O)[O-])s1","inchiKey":"YQNQNVDNTFHQSW-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"NITAZOXANIDE","yearOfFirstApproval":2002,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Alinia"],"synonyms":["NSC-697855","NSC-760057","Nitazoxanide","PH 5776","PH-5776"],"crossReferences":{"DailyMed":["nitazoxanide"],"PubChem":["124889979","144204569","144208424","170465090","17388853","26719875","49681590","525698"],"Wikipedia":["Nitazoxanide"],"drugbank":["DB00507"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and is indicated for diarrhea and has 22 investigational indications."}
{"id":"CHEMBL1419","canonicalSmiles":"CC(C)CC(N(C)C)C1(c2ccc(Cl)cc2)CCC1","inchiKey":"UNAANXDKBXWMLN-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SIBUTRAMINE","yearOfFirstApproval":1997,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":true,"isApproved":true,"withdrawnNotice":{"countries":["Canada"," China"," European Union"," Hong Kong"," India"," New Zealand"," United States"],"classes":["Cardiotoxicity"," Neurotoxicity"],"year":2010},"tradeNames":["Reductil"],"synonyms":["Butramin","Cf-alli","Medaria","Racemic sibutramine","Sibutramine"],"crossReferences":{"PubChem":["174007250","49732001"],"Wikipedia":["Sibutramine"],"drugbank":["DB01105"],"chEBI":["9137"]},"childChemblIds":["CHEMBL3989830","CHEMBL1200765"],"linkedTargets":{"rows":["ENSG00000108576","ENSG00000103546","ENSG00000142319"],"count":3},"linkedDiseases":{"rows":["MONDO_0005090","EFO_0000289","EFO_0001073"],"count":3},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for obesity and has 1 investigational indication. It was withdrawn in Canada,  China,  European Union,  Hong Kong,  India,  New Zealand and  United States initially in 2010 due to Cardiotoxicity and  Neurotoxicity."}
{"id":"CHEMBL144888","canonicalSmiles":"CC(C)OP(=O)(O)O","inchiKey":"QPPQHRDVPBTVEV-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PHOSPHORYLISOPROPANE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Phosphoric Acid Monoisopropyl Ester"],"crossReferences":{"drugbank":["DB03976"],"chEBI":["44052"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1456892","canonicalSmiles":"C[N+]1(C)CCC[C@H]1C(=O)[O-]","inchiKey":"CMUNUTVVOOHQPW-LURJTMIESA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1456892","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["11112915","26757007"],"drugbank":["DB04284"],"chEBI":["35280"]},"childChemblIds":["CHEMBL166795"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1512080","canonicalSmiles":"CN1C(=O)/C(=N\\NC(N)=S)c2ccccc21","inchiKey":"DLGSOJOOYHWROO-WQLSENKSSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"METHISAZONE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BW 33-T-57","BW-33-T-57","Methisazone","Metisazone","NSC-69811","NSC-70969"],"crossReferences":{"PubChem":["26757941"],"Wikipedia":["Metisazone"],"drugbank":["DB13641"]},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL151803","canonicalSmiles":"S=C1SCN(Cc2ccccc2)CN1Cc1ccccc1","inchiKey":"QFVAWNPSRQWSDU-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SULBENTINE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["D 47","Dibenzathione","Dibenzthion","NSC-150555","Sulbentine"],"crossReferences":{"PubChem":["144205485","29216291","50085920"],"drugbank":["DB13671"],"chEBI":["31477"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1624126","canonicalSmiles":"CN(CCO)CC(O)Cn1cnc2c1c(=O)n(C)c(=O)n2C","inchiKey":"DSFGXPJYDCSWTA-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"XANTHINOL","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB09092"]},"childChemblIds":["CHEMBL1560089"],"description":"Small molecule drug with a maximum clinical trial phase of IV and is indicated for cardiovascular disease."}
{"id":"CHEMBL1633","canonicalSmiles":"CN1CCC(=C2c3ccccc3CC(=O)c3sccc32)CC1.O=C(O)/C=C/C(=O)O","inchiKey":"YNQQEYBLVYAWNX-WLHGVMLRSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"KETOTIFEN FUMARATE","yearOfFirstApproval":1999,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL534","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Alaway","Ketotifen fumarate","Zaditen","Zaditor"],"synonyms":["HC 20,511 FUMARATE","HC-20511 FUMARATE","Ketotifen (as fumarate)","Ketotifen fumarate","Ketotifen hydrogen fumarate","NSC-757415"],"crossReferences":{"DailyMed":["ketotifen%20fumarate"],"PubChem":["26719657","26747554","26747555","49731996","50106521","50106522","50106523","56424131","855752"]},"linkedTargets":{"rows":["ENSG00000196639"],"count":1},"linkedDiseases":{"rows":["EFO_0003931","HP_0012532","MONDO_0002406","EFO_0009521","EFO_0007141","EFO_0000274","EFO_1001417"],"count":7},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 6 investigational indications."}
{"id":"CHEMBL1650818","canonicalSmiles":"CC(C)(C)C(=O)OCOC(=O)[C@@H]1N2C(=O)[C@@H](/N=C/N3CCCCCC3)[C@H]2SC1(C)C","inchiKey":"NPGNOVNWUSPMDP-UTEPHESZSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"AMDINOCILLIN PIVOXIL","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Coactabs","Selexid"],"synonyms":["Amdinocillin pivoxil","Pivmecillinam","Pivmecillinam hydrochloride","RO 10-9071","RO-10-9071"],"childChemblIds":["CHEMBL4303519"],"description":"Small molecule drug with a maximum clinical trial phase of IV and is indicated for bacterial disease."}
{"id":"CHEMBL1652465","canonicalSmiles":"CC(C)COC(=O)[C@H](Cc1ccccc1)NP(=O)(COCCn1cnc2c(NC3CC3)nc(N)nc21)N[C@@H](Cc1ccccc1)C(=O)OCC(C)C","inchiKey":"YTMOQFAFGKLYIW-CONSDPRKSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"GS-9191","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["GS-9191","Gs-9191"],"crossReferences":{"drugbank":["DB15084"]},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL17669","canonicalSmiles":"O=C1NC(=O)C(Cc2ccc3c(c2)CC[C@H](Cc2ccccc2)O3)S1","inchiKey":"MVDXXGIBARMXSA-PYUWXLGESA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ENGLITAZONE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Englitazone"],"crossReferences":{"drugbank":["DB14035"]},"childChemblIds":["CHEMBL3989578"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL177749","canonicalSmiles":"O=S(=O)(c1ccc2c(c1)CN[C@@H](CF)C2)N1CCSCC1","inchiKey":"SBUKSNPHYWXCDG-CYBMUJFWSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL177749","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07739"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL187785","canonicalSmiles":"CO[C@@H]1[C@@H](C(=O)O)O[C@H](O)[C@H](O)[C@H]1O","inchiKey":"WGLLPAPKWFDHHV-NRGGUMNKSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL187785","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB04303"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL188865","canonicalSmiles":"N#Cc1nc(Nc2ccccc2OCCCn2ccnc2)c2ncn(C3CCCC3)c2n1","inchiKey":"JJNKDTWKWYLERH-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL188865","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07967"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1893554","canonicalSmiles":"C[C@]12Cc3nonc3C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O","inchiKey":"RGLLOUBXMOGLDQ-IVEVATEUSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"FURAZABOL","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Frazalon","Furazabol","Miotolan","Qu zhi shu"],"crossReferences":{"PubChem":["144206325","50125887"],"drugbank":["DB01514"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1908841","canonicalSmiles":"Nc1nc(=O)c2c([nH]1)NC[C@H](CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1)N2C=O","inchiKey":"VVIAGPKUTFNRDU-STQMWFEESA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"LEVOLEUCOVORIN","yearOfFirstApproval":2008,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Khapzory"],"synonyms":["(6s)-leucovorin","(s)-leucovorin","L-folinic acid","LFP-754","Levofolene","Levofolinic acid","Levoleucovorin"],"crossReferences":{"DailyMed":["levoleucovorin","levoleucovorin%20calcium"],"drugbank":["DB11596"],"chEBI":["63606"]},"childChemblIds":["CHEMBL3707343","CHEMBL1908361"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and has 5 approved and 8 investigational indications."}
{"id":"CHEMBL2010601","canonicalSmiles":"CC(C)(C)c1cc(C(C)(C)C)c(NC(=O)c2c[nH]c3ccccc3c2=O)cc1O","inchiKey":"PURKAOJPTOLRMP-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"IVACAFTOR","yearOfFirstApproval":2012,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Kalydeco"],"synonyms":["Ivacaftor","VX-770"],"crossReferences":{"DailyMed":["ivacaftor"],"PubChem":["124950685"],"drugbank":["DB08820"],"chEBI":["66901"]},"childChemblIds":["CHEMBL4297603"],"linkedTargets":{"rows":["ENSG00000001626"],"count":1},"linkedDiseases":{"rows":["Orphanet_244","EFO_0007486","EFO_0000684","EFO_0001421","EFO_0006505","Orphanet_586","EFO_0000341","HP_0001657"],"count":8},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and is indicated for respiratory system disease and cystic fibrosis and has 6 investigational indications."}
{"id":"CHEMBL2064032","canonicalSmiles":"CNCc1cc(-c2ccccc2F)n(S(=O)(=O)c2cccnc2)c1.O=C(O)/C=C/C(=O)O","inchiKey":"ROGSHYHKHPCCJW-WLHGVMLRSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"VONOPRAZAN FUMARATE","maximumClinicalTrialPhase":3,"parentId":"CHEMBL2079130","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["TAK-438","TAK-438 monofumarate","Tak 438","Vonoprazan fumarate","Vonoprazan fumurate","Vonoprazan monofumarate"],"linkedTargets":{"rows":["ENSG00000105675","ENSG00000186009"],"count":2},"linkedDiseases":{"rows":["EFO_0003948","EFO_0009454","EFO_0004607","EFO_1000961"],"count":4},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL2068884","canonicalSmiles":"O=C([O-])[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O.[Na+]","inchiKey":"MSXHSNHNTORCAW-GGLLEASOSA-M","drugType":"Small molecule","blackBoxWarning":false,"name":"SODIUM GLUCONATE","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Bvd addicrete","Clewat gl","D-gluconic acid, monosodium salt","E-576","E-576-","E576","FEMA NO. 4934","Gluconate sodium","Gluconic acid sodium salt","Helshas a","INS NO.576","INS-576","Monosodium gluconate","NSC-759599","Natrum gluconicum","Sodium d-gluconate","Sodium gluconate"],"crossReferences":{"DrugCentral":["4214"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for hemorrhage and has 1 investigational indication."}
{"id":"CHEMBL2104184","canonicalSmiles":"CO/N=C/[C@@H]1[C@@H](c2ccc(Cl)c(Cl)c2)C[C@@H]2CC[C@H]1N2C","inchiKey":"NRLIFEGHTNUYFL-QJDHNRDASA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BRASOFENSINE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Brasofensine"],"crossReferences":{"drugbank":["DB04857"]},"childChemblIds":["CHEMBL2106525"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2104423","canonicalSmiles":"CC[C@@H](C(=O)[C@@H](C)[C@@H](O)[C@H](C)[C@@H]1O[C@@H]([C@@H](CC)C(=O)O)[C@@H](C)C[C@@H]1C)[C@H]1O[C@]2(C=C[C@@H](O)[C@]3(CC[C@@](C)([C@H]4CC[C@](O)(CC)[C@H](C)O4)O3)O2)[C@H](C)C[C@@H]1C","inchiKey":"VHKXXVVRRDYCIK-CWCPJSEDSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"NARASIN","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":["Monteban"],"synonyms":["Antibiotic a-28086 factor a","C-7819B","COMPD-79891","COMPOUND 79891","Narasin","Narasin a","Salinomycin, 4-methyl-, (4s)-"],"crossReferences":{"PubChem":["144206098"],"drugbank":["DB11432"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2105613","canonicalSmiles":"CCCC(CCC)C(=O)O.CCCC(CCC)C(=O)[O-].[Na+]","inchiKey":"MSRILKIQRXUYCT-UHFFFAOYSA-M","drugType":"Small molecule","blackBoxWarning":true,"name":"DIVALPROEX SODIUM","yearOfFirstApproval":1983,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL109","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Depakote","Depakote cp","Depakote er","Divalproex sodium"],"synonyms":["ABBOTT 50711","ABBOTT-50711","Divalproex","Divalproex sodium","Semisodium valproate","Valproate semisodium","Valproic acid sodium salt (2:1)"],"crossReferences":{"DailyMed":["divalproex%20sodium"],"chEBI":["4667"]},"linkedTargets":{"rows":["ENSG00000112294"],"count":1},"linkedDiseases":{"rows":["EFO_0000616","MONDO_0005090","EFO_1000877","EFO_0004777","HP_0010865","HP_0000726","EFO_0003015","EFO_0003758","EFO_0009963","EFO_0001358","HP_0001250","HP_0000713","MONDO_0005277","Orphanet_399","EFO_0004247","EFO_0000474","EFO_0000289","MONDO_0002050","MONDO_0004975","EFO_0003761","MONDO_0007079","EFO_0000717","EFO_0005411","HP_0002121","EFO_0009878"],"count":25},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1983 and has 6 approved and 14 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL2107011","canonicalSmiles":"COc1cc2[nH]c(C)c(CCN3CCN(c4ccccc4)CC3)c2cc1OC","inchiKey":"XCWPUUGSGHNIDZ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"OXYPERTINE","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Forit","Integrin"],"synonyms":["Oxipertine","Oxypertine","WIN 18,501-2","WIN-18501-2","WIN-185012"],"crossReferences":{"drugbank":["DB13403"]},"childChemblIds":["CHEMBL2360489"],"description":"Small molecule drug with a maximum clinical trial phase of IV and is indicated for psychosis."}
{"id":"CHEMBL2107909","drugType":"Unknown","blackBoxWarning":false,"name":"RABIES VACCINE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Rabies vaccine","Rabies vaccine adsorbed","Rabies vaccines"],"description":"Unknown drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL2108059","drugType":"Protein","blackBoxWarning":false,"name":"VELAFERMIN","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["CG-53135-05","CG53135-05","Velafermin"],"description":"Protein drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL2108139","drugType":"Small molecule","blackBoxWarning":false,"name":"POVIDONE","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":true,"isApproved":true,"withdrawnNotice":{"countries":["United States"]},"tradeNames":["Kollidon 25, 30, 12pf, 17pf, 90f","Plasdone","Vinisil"],"synonyms":["1-vinyl-2-pyrrolidinone polymer","E-1201","INS NO.1201","INS-1201","K30","K90)","NSC-114022","NSC-142693","Polyvidone","Polyvinylpyrrolidone","Polyvinylpyrrolidone (k25","Polyvinylpyrrolidone [k25, k30, k90]","Polyvinylpyrrolidone-(1201)","Povidone","Povidone, unspecified","Povidones","Povidonum"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 2 investigational indications. It was withdrawn in United States."}
{"id":"CHEMBL2108404","drugType":"Antibody","blackBoxWarning":false,"name":"EPRATUZUMAB","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":["Lymphocide"],"synonyms":["AMG-412","Epratuzumab","IMMU-HLL2","hLL2"],"linkedTargets":{"rows":["ENSG00000012124"],"count":1},"linkedDiseases":{"rows":["EFO_0009441","EFO_0000565","EFO_0002690","EFO_0000220","EFO_0000403","EFO_0000574","MONDO_0000870","EFO_0005952","EFO_0000094","EFO_0000311"],"count":10},"description":"Antibody drug with a maximum clinical trial phase of III (across all indications) and has 10 investigational indications."}
{"id":"CHEMBL2108518","drugType":"Unknown","blackBoxWarning":false,"name":"GELATIN","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Gelofusine","Gppe inf","Haemaccel","Isoplex","Volplex"],"synonyms":["Gelatin","Gelatin limed bone","Gelatin, unspecified","Gelatin,absorbable","Gelatin,absorbable film","Gelatin,absorbable powder","Gelatin,absorbable sponge","Gelatina","Gelatine"],"description":"Unknown drug with a maximum clinical trial phase of IV (across all indications) and has 9 investigational indications."}
{"id":"CHEMBL2108570","drugType":"Unknown","blackBoxWarning":true,"name":"ABOBOTULINUMTOXINA","yearOfFirstApproval":2009,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Abobotulinumtoxina","RTI-150","RTI150"],"crossReferences":{"DailyMed":["abobotulinumtoxina"]},"linkedTargets":{"rows":["ENSG00000132639"],"count":1},"linkedDiseases":{"rows":["EFO_1001896","MONDO_0000726","EFO_0006346","HP_0000951","HP_0030834","HP_0009762","HP_0000473","HP_0003419","EFO_0005422","Orphanet_304","EFO_1001145","Orphanet_1866"],"count":12},"description":"Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 3 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL2108696","drugType":"Unknown","blackBoxWarning":false,"name":"WHEAT BRAN","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Ae-wheat bran","Common wheat bran","Food - plant source, wheat bran","Triticum (wheat fibre)","Triticum aestivum bran","Triticum aestivum seed husk","Triticum hybernum bran","Triticum macha bran","Triticum sativum bran","Triticum sphaerococcum bran","Triticum vulgare (wheat) bran","Wheat bran","Wheat bran fiber","Wheat bran, crude","Wheat bran,crude"],"description":"Unknown drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL2108842","drugType":"Protein","blackBoxWarning":false,"name":"ALVIRCEPT SUDOTOX","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Alvircept sudotox","SCD4-PE40","U-85,855","U-85855"],"description":"Protein drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL2108963","drugType":"Small molecule","blackBoxWarning":false,"name":"HEMOGLOBIN RAFFIMER","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":["Hemolink"],"synonyms":["Hemoglobin raffimer"],"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL2109398","drugType":"Antibody","blackBoxWarning":false,"name":"KB-004","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["KB-004","Kb-004"],"linkedTargets":{"rows":["ENSG00000044524"],"count":1},"linkedDiseases":{"rows":["EFO_0002430","EFO_0000198","EFO_0000519"],"count":3},"description":"Antibody drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL2109437","drugType":"Antibody","blackBoxWarning":false,"name":"KHK-2866","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["KHK-2866","KHK2866","Khk-2866"],"linkedTargets":{"rows":["ENSG00000113070"],"count":1},"linkedDiseases":{"rows":["EFO_0003893","EFO_1001100","EFO_1000251"],"count":3},"description":"Antibody drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL2109602","drugType":"Antibody","blackBoxWarning":false,"name":"IMC-3C5","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["IMC-3C5","Imc-3c5"],"linkedTargets":{"rows":["ENSG00000037280"],"count":1},"linkedDiseases":{"rows":["EFO_0000616"],"count":1},"description":"Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL2110824","canonicalSmiles":"CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1","inchiKey":"CUWODFFVMXJOKD-UVLQAERKSA-N","drugType":"Protein","blackBoxWarning":false,"name":"BUSERELIN","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Suprecur","Suprefact"],"synonyms":["Buserelin"],"childChemblIds":["CHEMBL2106198"],"linkedTargets":{"rows":["ENSG00000109163"],"count":1},"linkedDiseases":{"rows":["EFO_0000616","Orphanet_64739","EFO_0000545","EFO_0000673","EFO_0000196","MONDO_0008315","EFO_0002950"],"count":7},"description":"Protein drug with a maximum clinical trial phase of IV (across all indications) and is indicated for neoplasm and has 4 investigational indications."}
{"id":"CHEMBL2110924","canonicalSmiles":"CNCCCC1(C)CN(c2ccccc2)c2ccccc21","inchiKey":"YFAIJBZEDDOCAN-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DALEDALIN","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Daledalin"],"crossReferences":{"drugbank":["DB09189"]},"childChemblIds":["CHEMBL2106675"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL211769","canonicalSmiles":"COC(=O)C[C@H]1CC(c2ccc(O)cc2)=NO1","inchiKey":"AIXMJTYHQHQJLU-SNVBAGLBSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL211769","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07888"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2219536","canonicalSmiles":"COCCO[C@H]1[C@@H](O)[C@H](COP(=O)(O)S[C@H]2[C@H](COP(=O)(O)S[C@H]3[C@H](COP(=O)(O)S[C@H]4[C@H](COP(=O)(O)S[C@H]5[C@@H](OCCOC)[C@H](n6cnc7c(=O)[nH]c(N)nc76)O[C@@H]5COP(=O)(O)S[C@H]5C[C@H](n6cc(C)c(N)nc6=O)O[C@@H]5COP(=O)(O)S[C@H]5C[C@H](n6cc(C)c(=O)[nH]c6=O)O[C@@H]5COP(=O)(O)S[C@H]5C[C@H](n6cc(C)c(=O)[nH]c6=O)O[C@@H]5COP(=O)(O)S[C@H]5C[C@H](n6cc(C)c(N)nc6=O)O[C@@H]5COP(=O)(O)S[C@H]5C[C@H](n6cnc7c(=O)[nH]c(N)nc76)O[C@@H]5COP(=O)(O)S[C@H]5C[C@H](n6cc(C)c(=O)[nH]c6=O)O[C@@H]5COP(=O)(O)S[C@H]5C[C@H](n6cc(C)c(N)nc6=O)O[C@@H]5COP(=O)(O)S[C@H]5C[C@H](n6cc(C)c(=O)[nH]c6=O)O[C@@H]5COP(=O)(O)S[C@H]5C[C@H](n6cnc7c(=O)[nH]c(N)nc76)O[C@@H]5COP(=O)(O)S[C@H]5C[C@H](n6cnc7c(N)ncnc76)O[C@@H]5COP(=O)(O)S[C@H]5[C@@H](OCCOC)[C@H](n6cc(C)c(N)nc6=O)O[C@@H]5COP(=O)(O)S[C@H]5[C@@H](OCCOC)[C@H](n6cc(C)c(=O)[nH]c6=O)O[C@@H]5COP(=O)(O)S[C@H]5[C@@H](OCCOC)[C@H](n6cc(C)c(N)nc6=O)O[C@@H]5COP(=O)(O)S[C@H]5[C@@H](OCCOC)[C@H](n6cc(C)c(N)nc6=O)O[C@@H]5COP(=O)(O)S[C@H]5[C@@H](OCCOC)[C@H](n6cnc7c(=O)[nH]c(N)nc76)O[C@@H]5CO)O[C@H](n5cc(C)c(N)nc5=O)[C@H]4OCCOC)O[C@H](n4cnc5c(N)ncnc54)[C@H]3OCCOC)O[C@H](n3cc(C)c(N)nc3=O)[C@H]2OCCOC)O[C@@H]1n1cc(C)c(N)nc1=O","inchiKey":"TZRFSLHOCZEXCC-HIVFKXHNSA-N","drugType":"Oligonucleotide","blackBoxWarning":true,"name":"MIPOMERSEN","yearOfFirstApproval":2013,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Mipomersen"],"crossReferences":{"DailyMed":["mipomersen%20sodium"],"DrugCentral":["4747"]},"childChemblIds":["CHEMBL502097"],"linkedTargets":{"rows":["ENSG00000084674"],"count":1},"linkedDiseases":{"rows":["HP_0003124","EFO_0000319","EFO_0004911"],"count":3},"description":"Oligonucleotide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and is indicated for cardiovascular disease and familial hypercholesterolemia and has 1 investigational indication. This drug has a black box warning from the FDA."}
{"id":"CHEMBL2323775","canonicalSmiles":"Cn1cc(-c2cnc3ccc4ccc(CS(=O)(=O)NCc5ccccn5)cc4c(=O)c3c2)cn1","inchiKey":"VMJFTOSOFDEKTM-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"MK-8033","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["MK-8033","MK8033","Mk-8033"],"linkedTargets":{"rows":["ENSG00000164078","ENSG00000105976"],"count":2},"linkedDiseases":{"rows":["EFO_0000311"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL2387541","canonicalSmiles":"CCCc1cc(O)c2c(c1)OC(C)(C)[C@@H]1CCC(C)=C[C@@H]21","inchiKey":"ZROLHBHDLIHEMS-HUUCEWRRSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TETRAHYDROCANNABIVARIN","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[".delta.9-tetrahydrocannabivarin","GWP-42004","GWP42004","Gwp42004","O-4394","THCV","Tetrahydrocannabivarin","Thc-v"],"crossReferences":{"drugbank":["DB11755"]},"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL289556","canonicalSmiles":"O=C(N[C@H]1CCS[C@H]2CCC[C@@H](C(=O)O)N2C1=O)[C@@H](S)Cc1ccccc1","inchiKey":"LVRLSYPNFFBYCZ-VGWMRTNUSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"OMAPATRILAT","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BMS-186716","BMS-186716-01","Omapatrilat"],"crossReferences":{"Wikipedia":["Omapatrilat"],"drugbank":["DB00886"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL307500","canonicalSmiles":"C[C@]12CC[C@@H]3[C@H]4CC[C@H](O)C=C4CC[C@H]3[C@@H]1CC[C@@H]2O","inchiKey":"CMXKUJNZWYTFJN-XFUVECHXSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL307500","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB01554"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3099695","canonicalSmiles":"N#Cc1ccc([C@H]2CCc3cncn32)c(F)c1","inchiKey":"USUZGMWDZDXMDG-CYBMUJFWSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"OSILODROSTAT","yearOfFirstApproval":2020,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["LCI-699-NX","LCI699-NX","Lci-699","Lci699","Osilodrostat"],"crossReferences":{"DailyMed":["osilodrostat%20phosphate"],"drugbank":["DB11837"]},"childChemblIds":["CHEMBL3707393"],"linkedTargets":{"rows":["ENSG00000160882"],"count":1},"linkedDiseases":{"rows":["EFO_0005539","EFO_0003086","MONDO_0001134","EFO_0003099","EFO_0001421","HP_0011736","EFO_1001110","EFO_0000537"],"count":8},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for pituitary-dependent cushing's disease and adrenal gland disease and has 7 investigational indications."}
{"id":"CHEMBL31088","canonicalSmiles":"CNCCc1ccc(O)c(O)c1","inchiKey":"NGKZFDYBISXGGS-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DEOXIEPINEPHRINE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["11111083","124879903","26755669","90341311"],"Wikipedia":["Deoxyepinephrine"],"drugbank":["DB13917"],"chEBI":["10554"]},"childChemblIds":["CHEMBL1256484"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL311932","canonicalSmiles":"COc1ccc(S(=O)(=O)N(CC(=O)NO)CC(C)C)cc1","inchiKey":"JIRXORZYIXSWOB-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL311932","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB08271"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL312948","canonicalSmiles":"CCC(=O)N(c1ccccc1)C1(c2ccccc2)CCN(CCc2ccccc2)CC1","inchiKey":"BXCJXJLHYMWMQU-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL312948","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB09168"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3137327","canonicalSmiles":"CC/C=C\\C/C=C\\C/C=C\\C/C=C\\C/C=C\\C/C=C\\CCC(=O)O.CC/C=C\\C/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCC(=O)O.CC/C=C\\C/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCCC(=O)O.CC/C=C\\C/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCCCC(=O)O.CC/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCCCCC(=O)O.CC/C=C\\C/C=C\\C/C=C\\CCCCCCCC(=O)O.CCCCC/C=C\\C/C=C\\C/C=C\\C/C=C\\C/C=C\\CCC(=O)O.CCCCC/C=C\\C/C=C\\C/C=C\\CCCCC(=O)O.CCCCC/C=C\\C/C=C\\CCCCCCCC(=O)O","inchiKey":"QIQSYARFOIKJJR-LUTWCBITSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"OMEGA-3-CARBOXYLIC ACIDS","yearOfFirstApproval":2014,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Epanova"],"synonyms":["Omega-3 carboxylic acid","Omega-3-carboxylic acids"],"crossReferences":{"DrugCentral":["5126"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 2 investigational indications."}
{"id":"CHEMBL3188292","canonicalSmiles":"O=[Si]=O","inchiKey":"VYPSYNLAJGMNEJ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL3188292","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["144211605"],"drugbank":["DB11132"],"chEBI":["30563"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL323533","canonicalSmiles":"C[C@]12CC[C@H]3C(=CCc4cc(O)ccc43)[C@@H]1CCC2=O","inchiKey":"WKRLQDKEXYKHJB-HFTRVMKXSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"EQUILIN","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Equilin","NSC-10971"],"crossReferences":{"PubChem":["144212958","56422880","8139975"],"Wikipedia":["Equilin"],"drugbank":["DB02187"],"chEBI":["42309"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL325414","canonicalSmiles":"O=C(O)CC[C@H](NC(=O)c1ccc(S(=O)(=O)N2CCC[C@@H]2C(=O)O)cc1)C(=O)O","inchiKey":"NDDOUBGQRWFVQM-QWHCGFSZSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL325414","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB04503"],"chEBI":["46068"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL329091","canonicalSmiles":"Nc1ncc2ncn(CC3(OCP(=O)(O)O)CC3)c2n1","inchiKey":"KDNSSKPZBDNJDF-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"LB80331","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["LB80331"],"crossReferences":{"drugbank":["DB15671"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3301574","drugType":"Cell","blackBoxWarning":false,"name":"TISAGENLECLEUCEL","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["CART-19","CART19","CTL-019","CTL019","Car.cd19-redirected t cells","Kymriah","Tisagenlecleucel","Tisagenlecleucel-t"],"linkedTargets":{"rows":["ENSG00000177455"],"count":1},"linkedDiseases":{"rows":["EFO_0002618","EFO_0000616","MONDO_0000873","EFO_0000220","EFO_0000403","EFO_1000157","EFO_0000222","EFO_1001469","EFO_0005952","EFO_0000565","EFO_0000096","EFO_0000095","EFO_0000574","EFO_0001378","MONDO_0018906","EFO_0000183","EFO_0000094"],"count":17},"description":"Cell drug with a maximum clinical trial phase of IV (across all indications) and is indicated for neoplasm and has 15 investigational indications."}
{"id":"CHEMBL3353410","canonicalSmiles":"C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C","inchiKey":"DUYJMQONPNNFPI-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"OSIMERTINIB","yearOfFirstApproval":2015,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Tagrisso"],"synonyms":["AZD-9291","AZD-9291 FREE BASE","AZD9291","Azd-9291","Mereletinib","Osimertinib"],"crossReferences":{"DailyMed":["osimertinib%20mesylate"],"drugbank":["DB09330"]},"childChemblIds":["CHEMBL4741340","CHEMBL4754013","CHEMBL3545063","CHEMBL4472934","CHEMBL4784911"],"linkedTargets":{"rows":["ENSG00000146648"],"count":1},"linkedDiseases":{"rows":["EFO_0000616","MONDO_0021117","MONDO_0008903","EFO_0000571","EFO_0005842","EFO_0000313","EFO_0000707","MONDO_0024880","EFO_0000228","EFO_0003060","EFO_0000519","EFO_0003833","EFO_0000311"],"count":13},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 3 approved and 8 investigational indications."}
{"id":"CHEMBL337577","canonicalSmiles":"N[C@@H](Cn1c2c(c(=O)[nH]c1=O)CCC2)C(=O)O","inchiKey":"VSGUEKZRMJVQOH-LURJTMIESA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL337577","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["29215506"],"drugbank":["DB03240"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL35241","canonicalSmiles":"N=C(N)c1ccc(/N=N/Nc2ccc(C(=N)N)cc2)cc1","inchiKey":"XNYZHCFCZNMTFY-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DIMINAZENE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["4,4'-(diazoamino)benzamidine","Diminazen","Diminazene"],"crossReferences":{"drugbank":["DB03608"],"chEBI":["81724"]},"childChemblIds":["CHEMBL380216","CHEMBL124025"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3527358","canonicalSmiles":"CO[C@H]1[C@H]([C@@]2(C)O[C@@H]2CC=C(C)C)[C@]2(CC[C@H]1OC(=O)N[C@@H](C(N)=O)C(C)C)CO2","inchiKey":"QBDVVYNLLXGUGN-XGTBZJOHSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PPI-2458","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Ppi-2458"],"crossReferences":{"drugbank":["DB05864"]},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL353581","canonicalSmiles":"O=C(CCCCCCC(=O)Nc1cccnc1)NO","inchiKey":"PTJGLFIIZFVFJV-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PYROXAMIDE","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Octanedioic acid hydroxyamide pyridin-3-ylamide","Pyroxamide"],"crossReferences":{"PubChem":["524991"],"drugbank":["DB12847"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3545204","drugType":"Small molecule","blackBoxWarning":false,"name":"QAF805","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Qaf805"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3545301","drugType":"Small molecule","blackBoxWarning":false,"name":"HMPL-523","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Hmpl-523"],"linkedTargets":{"rows":["ENSG00000165025"],"count":1},"linkedDiseases":{"rows":["EFO_0000616","EFO_0007160","EFO_0000685","EFO_0000222","EFO_0005952","EFO_0000311"],"count":6},"description":"Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 6 investigational indications."}
{"id":"CHEMBL3545331","drugType":"Small molecule","blackBoxWarning":false,"name":"RPR749","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Rpr749"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3545352","drugType":"Small molecule","blackBoxWarning":false,"name":"P-1037","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["P-1037"],"linkedTargets":{"rows":["ENSG00000166828","ENSG00000168447","ENSG00000111319"],"count":3},"linkedDiseases":{"rows":["Orphanet_586"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL362592","canonicalSmiles":"CC(C)C[C@H](NC(=O)[C@@H]1CC(=O)NCCCCCCOC(=O)N[C@@H](C(C)C)C(=O)N1)[C@@H](O)C[C@@H](C)C(=O)N[C@H](C(=O)NCc1ccccc1)C(C)C","inchiKey":"QJAPFAZHNSZLJE-CWURXVSKSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL362592","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB02378"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3696475","canonicalSmiles":"Cc1c([C@@H](O)CN2CCN(C[C@H](O)c3ccc4c(c3C)COC4=O)CC2)ccc2c1COC2=O","inchiKey":"OCKGFTQIICXDQW-ZEQRLZLVSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"MK-7145","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Mk-7145"],"crossReferences":{"drugbank":["DB11968"]},"description":"Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL3707401","drugType":"Small molecule","blackBoxWarning":false,"name":"MK-8777","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Mk-8777","Org-26576"],"linkedTargets":{"rows":["ENSG00000125675","ENSG00000120251","ENSG00000155511","ENSG00000152578"],"count":4},"linkedDiseases":{"rows":["EFO_0003888","MONDO_0002050"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL3833371","canonicalSmiles":"CC(C)OC(=O)[C@@H](C)N[P@@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(Cl)[C@@H]1O)Oc1ccccc1","inchiKey":"SFPFZQKYPOWCSI-KHFYHRBSSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"UPRIFOSBUVIR","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["IDX-21437","IDX21437","MK-3682","Uprifosbuvir"],"crossReferences":{"drugbank":["DB15206"]},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL389029","canonicalSmiles":"NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)C[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O","inchiKey":"DBLVDAUGBTYDFR-SWMBIRFSSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"LIVIDOMYCIN","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Lividomycin","Lividomycin a"],"crossReferences":{"drugbank":["DB04728"],"chEBI":["71961"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3948730","canonicalSmiles":"CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F","inchiKey":"IUVCFHHAEHNCFT-INIZCTEOSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"UMBRALISIB","yearOfFirstApproval":2021,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["RP-5264","RP5264","TGR-1202 FREE BASE","TGR-1202 base","Tgr 1202","Umbralisib"],"crossReferences":{"drugbank":["DB14989"]},"childChemblIds":["CHEMBL3989869"],"linkedTargets":{"rows":["ENSG00000171608","ENSG00000097007","ENSG00000213923"],"count":3},"linkedDiseases":{"rows":["EFO_0009441","EFO_0002618","MONDO_0044903","EFO_0000403","EFO_1000657","Orphanet_44890","MONDO_0007576","EFO_1001469","EFO_0002429","EFO_1001951","EFO_0000211","MONDO_0001056","EFO_0000096","EFO_0000095","EFO_1000630","MONDO_0018906","EFO_0000183"],"count":17},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for marginal zone b-cell lymphoma and follicular lymphoma and has 19 investigational indications."}
{"id":"CHEMBL3989731","canonicalSmiles":"C[C@H](N)Cc1cccc(O)c1","inchiKey":"WTDGMHYYGNJEKQ-ZETCQYMHSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"GEPEFRINE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["D-.alpha.-methyl-m-tyramine","Gepefrine"],"crossReferences":{"drugbank":["DB13703"]},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL3989931","canonicalSmiles":"CC(C)(O)CNc1nc(Nc2ccnc(C(F)(F)F)c2)nc(-c2cccc(C(F)(F)F)n2)n1.CS(=O)(=O)O","inchiKey":"ORZHZQZYWXEDDL-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"ENASIDENIB MESYLATE","yearOfFirstApproval":2017,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL3989908","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Idhifa"],"synonyms":["AG-221 mesylate","CC-90007","Enasidenib mesilate","Enasidenib mesylate","Enasidenib methanesulfonate"],"crossReferences":{"DailyMed":["enasidenib%20mesylate"]},"linkedTargets":{"rows":["ENSG00000182054"],"count":1},"linkedDiseases":{"rows":["EFO_0000222"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2017 and is indicated for acute myeloid leukemia. This drug has a black box warning from the FDA."}
{"id":"CHEMBL3989959","canonicalSmiles":"NCCONC(=O)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(=O)(=O)O","inchiKey":"RSBPYSTVZQAADE-RQJHMYQMSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"NACUBACTAM","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["FPI-1459","Nacubactam","RG-6080","RG6080","RO-7079901","RO7079901"],"crossReferences":{"drugbank":["DB15353"]},"description":"Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL405886","canonicalSmiles":"O=C(O)c1ccc2c(c1)C(=O)N([C@H](Cc1cccc3ccccc13)C(=O)O)C2=O","inchiKey":"CZNPWASYMRBJCX-GOSISDBHSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL405886","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["26740854","99495572"],"drugbank":["DB06922"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL4297288","canonicalSmiles":"Cc1ccc(=O)n(-c2ccc(O)cc2)c1","inchiKey":"NETTXQJYJRFTFS-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"HYDRONIDONE","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["F 351","F-351","Hydronidone"],"crossReferences":{"drugbank":["DB06299"]},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL4297392","canonicalSmiles":"O=C(NCc1ccc(Oc2ccccc2)cc1)c1nc(-c2cc(Br)c(O)c(Br)c2)no1","inchiKey":"DSFNLJXHXBIKDS-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"IOWH-032","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Iowh-032","Iowh032"],"crossReferences":{"drugbank":["DB12959"]},"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL4297495","canonicalSmiles":"C[N+](C)(C)CCOP(=O)([O-])OCCCCCCCCCCCCCCCCCCc1ccc([131I])cc1","inchiKey":"ZOAIEFWMQLYMTF-YRKXUXMHSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"NM-404 I-131","maximumClinicalTrialPhase":2,"parentId":"CHEMBL208375","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["131I-CLR1404","131I-NM-404","CLR-131","CLR-1404 I-131","CLR131","I-131-CLR1404","I-131-clr1404","NM-404 I-131","Nm-404 i-131"],"crossReferences":{"drugbank":["DB15244"]},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL4297529","canonicalSmiles":"C[C@@H](O)[C@H](NC(=O)[C@H](CS(=O)(=O)O)NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)CN)C(=O)N1CCC[C@H]1C(=O)O","inchiKey":"MYZAXBZLEILEBR-RVFOSREFSA-N","drugType":"Protein","blackBoxWarning":false,"name":"RISUTEGANIB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":["Luminate"],"synonyms":["ALG-1001","ALG-1001 HEXAPEPTIDE","ALG1001","Alg-1001","GLY-ARG-GLY-CYA-THR-PRO","Risuteganib"],"crossReferences":{"drugbank":["DB14911"]},"description":"Protein drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL4297695","drugType":"Unknown","blackBoxWarning":false,"name":"AQ-13","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Aq 13","Aq-13"],"description":"Unknown drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL4297747","drugType":"Unknown","blackBoxWarning":false,"name":"ENDOSTATIN","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Endostatin","YH 16","YH-16"],"description":"Unknown drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications."}
{"id":"CHEMBL4297790","drugType":"Unknown","blackBoxWarning":false,"name":"MVT-1075","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["177lu-chx-a'-dtpa-humab-5b1","MONO-177LU-DTPA-MVT-5873","MVT-1075","Mvt-1075"],"description":"Unknown drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL4297908","drugType":"Antibody","blackBoxWarning":false,"name":"CEVOSTAMAB","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BFCR-4350A","BFCR4350A","Bfcr-4350a","Bfcr4350a","Cevostamab","RO-7187797","RO7187797"],"description":"Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL4297940","drugType":"Protein","blackBoxWarning":false,"name":"ACLERASTIDE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Aclerastide","Asp-arg-nle-tyr-ile-his-pro","DSC127","Dsc-127","Dsc127","Norleu3-a(1-7)","Norleu3-angiotensin(1-7)","USB-001","USB-005","USB005"],"description":"Protein drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL4298202","drugType":"Oligonucleotide","blackBoxWarning":false,"name":"PELACARSEN","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AKCEA-APO(a)-LRx","ISIS 681257","ISIS-681257 FREE ACID","Ionis-apo(a)-lrx","Pelacarsen"],"description":"Oligonucleotide drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL4526356","canonicalSmiles":"C[C@]12CC[C@@H]3c4ccc(B(O)O)cc4C[C@@H](CCCCCCCCC[S+]([O-])CCCC(F)(F)C(F)(F)F)[C@H]3[C@@H]1CC[C@@H]2O","inchiKey":"FIAYIYKWRBIBQG-GDWZZRAASA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ZB-716","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Fulvestrant-3-boronic acid","Zb-716","Zb716"],"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL458997","canonicalSmiles":"CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)ncc1Cl","inchiKey":"UYJNQQDJUOUFQJ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL458997","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["103904601"],"drugbank":["DB07460"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL4594318","drugType":"Protein","blackBoxWarning":false,"name":"INBAKICEPT","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Inbakicept","N-803"],"description":"Protein drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL4594421","canonicalSmiles":"[2H]C([2H])([2H])NC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F","inchiKey":"WXCXUHSOUPDCQV-HPRDVNIFSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"HC-1119","maximumClinicalTrialPhase":3,"parentId":"CHEMBL1082407","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Enzalutamide d3","HC 1119","HC-1119","Hc-1119"],"description":"Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL46058","canonicalSmiles":"CCCl","inchiKey":"HRYZWHHZPQKTII-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ETHYL CHLORIDE","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Chloroethane","Ethyl Chloride","Ethyl chloride"],"crossReferences":{"Wikipedia":["Chloroethane"],"drugbank":["DB13259"],"chEBI":["47554"]},"description":"Small molecule drug with a maximum clinical trial phase of IV and has 1 investigational indication."}
{"id":"CHEMBL46286","canonicalSmiles":"COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@@H]1C(OC)=C[C@]23CCCN2CCc2cc4c(cc2[C@H]13)OCO4","inchiKey":"HYFHYPWGAURHIV-JFIAXGOJSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"OMACETAXINE MEPESUCCINATE","yearOfFirstApproval":2009,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Synribo"],"synonyms":["CGX-635","Ceflatonin","HOMOHARRINGTONINE","Homoharringtonin","Myelostat","NSC-141633","Omacetaxine mepesuccinate","Omapro"],"crossReferences":{"DailyMed":["omacetaxine%20mepesuccinate"],"PubChem":["427112"],"drugbank":["DB04865"],"chEBI":["71019"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and is indicated for cancer and neoplasm and has 4 investigational indications."}
{"id":"CHEMBL4650215","canonicalSmiles":"C[C@H](Nc1ccc2c(c1)OCCn1cc(N3C(=O)OC[C@H]3C(F)F)nc1-2)C(N)=O","inchiKey":"SGEUNORSOZVTOL-CABZTGNLSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"INAVOLISIB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["GDC-0077","GDC0077","Gdc-0077","Inavolisib","RG-6114","RG6114","RO-7113755","RO7113755"],"linkedTargets":{"rows":["ENSG00000121879"],"count":1},"linkedDiseases":{"rows":["EFO_0000616","EFO_1001480","MONDO_0007254","EFO_0000311"],"count":4},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL4650368","canonicalSmiles":"COc1ncc(C)c(-c2ccc3c(c2)[nH]c(=O)c2cnn([C@H]4CCOC4)c23)c1C","inchiKey":"CKJDCNZBABIEBZ-HNNXBMFYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"IRSENONTRINE","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["E-2027","E2027","ER-592221-00","Irsenontrine"],"childChemblIds":["CHEMBL4650224"],"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL467","canonicalSmiles":"NC(=O)NO","inchiKey":"VSNHCAURESNICA-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"HYDROXYUREA","yearOfFirstApproval":1967,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Droxia","Hydrea","Hydroxyurea","Siklos"],"synonyms":["Hydroxycarbamide","Hydroxyurea","NSC-32065","SQ 1089","SQ-1089"],"crossReferences":{"DailyMed":["hydroxyurea"],"PubChem":["11111283","144210638","170465025","174007362","26747533","50106399","57260119","85231078","90341681","90752"],"Wikipedia":["Hydroxycarbamide"],"drugbank":["DB01005"],"chEBI":["44423"]},"linkedTargets":{"rows":["ENSG00000171848"],"count":1},"linkedDiseases":{"rows":["EFO_0008525","MONDO_0044903","EFO_0005577","Orphanet_232","EFO_0000756","EFO_1001465","EFO_0003866","Orphanet_848","MONDO_0020657","MONDO_0003212","EFO_0003817","EFO_0000565","EFO_0002430","MONDO_0001056","EFO_0004251","EFO_0000339","EFO_1001797","HP_0001871","MONDO_0008903","EFO_0000712","Orphanet_2495","EFO_0000707","EFO_1000158","EFO_0000479","EFO_1000388","EFO_0000198","EFO_0000616","MONDO_0005149","EFO_0006859","EFO_0000220","EFO_1000642","EFO_0009907","EFO_0000222","MONDO_0007576","EFO_0000313","EFO_0002429","EFO_0000224","EFO_0005570","MONDO_0005301","Orphanet_231222","EFO_0000764","EFO_0000574","EFO_0000519"],"count":43},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1967 and has 5 approved and 35 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL470670","canonicalSmiles":"CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O","inchiKey":"NOOLISFMXDJSKH-KXUCPTDWSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"LEVOMENTHOL","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["L-menthol","Levomenthol"],"crossReferences":{"PubChem":["144205173","144209021","144209117","144209806","144213316","144213345"],"Wikipedia":["Menthol"],"drugbank":["DB00825"],"chEBI":["15409"]},"description":"Small molecule drug with a maximum clinical trial phase of III."}
{"id":"CHEMBL476937","canonicalSmiles":"NS(=O)(=O)Oc1ccc2c(c1)S(=O)(=O)C(CC1CCCCCC1)=C2","inchiKey":"BIASYWBGUYOWJR-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"EMD-486019","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["EMD-486019"],"crossReferences":{"drugbank":["DB06954"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL477772","canonicalSmiles":"Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O","inchiKey":"CUIHSIWYWATEQL-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"PAZOPANIB","yearOfFirstApproval":2009,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Votrient"],"synonyms":["GW786034","NSC-752782","Pazopanib"],"crossReferences":{"DailyMed":["pazopanib%20hydrochloride"],"PubChem":["103905642","144206725","170465625","50100102"],"Wikipedia":["Pazopanib"],"drugbank":["DB06589"],"chEBI":["71219"]},"childChemblIds":["CHEMBL1201733"],"linkedTargets":{"rows":["ENSG00000134853","ENSG00000128052","ENSG00000068078","ENSG00000182866","ENSG00000102755","ENSG00000037280","ENSG00000077782","ENSG00000157404","ENSG00000113721","ENSG00000182578","ENSG00000113263"],"count":11},"linkedDiseases":{"rows":["EFO_0003869","EFO_0000637","EFO_0000365","EFO_0000756","EFO_0000681","Orphanet_79383","EFO_0000333","EFO_1000880","EFO_0000588","EFO_0000564","MONDO_0002974","EFO_0000389","MONDO_0008903","EFO_0000182","EFO_0000501","EFO_0000676","EFO_0000641","EFO_0000514","MONDO_0015277","MONDO_0018352","EFO_0002618","EFO_0003893","MONDO_0008170","EFO_0000349","EFO_1001968","MONDO_0016238","MONDO_0004986","MONDO_0008315","EFO_0001663","EFO_0007143","EFO_1001100","EFO_0000335","EFO_0000574","EFO_0006544","EFO_1000613","EFO_0003016","MONDO_0021640","EFO_0000569","EFO_1001901","MONDO_0004192","EFO_1001465","MONDO_0007254","MONDO_0002087","MONDO_0020654","MONDO_0001187","EFO_0009606","Orphanet_892","MONDO_0001056","MONDO_0002158","EFO_0003968","EFO_1001974","EFO_1000315","Orphanet_31112","MONDO_0012825","EFO_0000673","EFO_0000326","EFO_0002914","EFO_0000616","EFO_1000314","Orphanet_44890","MONDO_0000521","EFO_0000222","EFO_0003060","EFO_0000311","EFO_0000640","EFO_0006861","EFO_0002892","Orphanet_774","EFO_0000702","MONDO_0002367","MONDO_0024880","EFO_0000691","EFO_0000519","EFO_0000181"],"count":74},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 9 approved and 64 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL4802156","canonicalSmiles":"CC(=O)N(C)C1CCN(c2cccc(-c3ccc4nc(-c5cccnc5N)n(-c5ccc(C6(N)CCC6)cc5)c4n3)c2)CC1","inchiKey":"NZDSLYATTDIDPH-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"VEVORISERTIB","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Vevorisertib"],"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL490672","canonicalSmiles":"CCc1cc(CC[C@]2(C3CCCC3)CC(O)=C(Cc3nc4nc(C)cc(C)n4n3)C(=O)O2)cc(CC)n1","inchiKey":"SLVAPEZTBDBAPI-GDLZYMKVSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"FILIBUVIR","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Filibuvir","PF-00868554","PF-868554"],"crossReferences":{"drugbank":["DB11878"]},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL515914","canonicalSmiles":"CC(=O)OC[C@H]1O[C@@H](n2ncc(=O)[nH]c2=O)[C@H](OC(C)=O)[C@@H]1OC(C)=O","inchiKey":"QQOBRRFOVWGIMD-OJAKKHQRSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"AZARIBINE","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":true,"isApproved":true,"withdrawnNotice":{"countries":["United States"],"classes":["Vascular toxicity"],"year":1976},"tradeNames":["Triazure"],"synonyms":["Azaribine","CB 304","CB-304","NSC-67239"],"crossReferences":{"PubChem":["144204429","170466075","29215005","855722"]},"description":"Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in United States  in 1976 due to Vascular toxicity."}
{"id":"CHEMBL518647","canonicalSmiles":"CC(C)[C@H]1C(O)=C(C2=NS(=O)(=O)c3ccccc32)C(=O)N1Cc1ccccc1","inchiKey":"XKOAFAIRGVAHRA-IBGZPJMESA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL518647","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07414"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL519160","canonicalSmiles":"C/C(O)=C(\\C#N)C(=O)Nc1ccc(-c2ccccc2)cc1","inchiKey":"MUVPBAIVOHJDOC-VBKFSLOCSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL519160","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07443"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL550755","canonicalSmiles":"Cl.O=c1[nH]cnc2c([C@@H]3N[C@H](CO)[C@@H](O)[C@H]3O)c[nH]c12","inchiKey":"WEIAMZKHBCLFOG-QPAIBFMUSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"FORODESINE HYDROCHLORIDE","maximumClinicalTrialPhase":2,"parentId":"CHEMBL218291","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BCX-1777","Forodesine hcl","Forodesine hydrochloride"],"linkedTargets":{"rows":["ENSG00000198805"],"count":1},"linkedDiseases":{"rows":["EFO_0000095","EFO_0004289","EFO_0000574","EFO_0000311","MONDO_0000430"],"count":5},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."}
{"id":"CHEMBL598797","canonicalSmiles":"C#Cc1cccc(Nc2ncnc3cc(OC)c(OCCCCCCC(=O)NO)cc23)c1","inchiKey":"PLIVFNIUGLLCEK-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CUDC-101","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["CUDC-101","Cudc 101","Cudc-101"],"crossReferences":{"PubChem":["137276021"],"drugbank":["DB12174"]},"childChemblIds":["CHEMBL3922781","CHEMBL3957601","CHEMBL3983283","CHEMBL3913031"],"linkedTargets":{"rows":["ENSG00000146648","ENSG00000108840","ENSG00000094631","ENSG00000061273","ENSG00000147099","ENSG00000068024","ENSG00000116478","ENSG00000163517","ENSG00000100429","ENSG00000171720","ENSG00000141736","ENSG00000048052","ENSG00000196591"],"count":13},"linkedDiseases":{"rows":["EFO_0000616","MONDO_0001056","MONDO_0002691","EFO_0006859","MONDO_0007254","EFO_0003060","EFO_0000311"],"count":7},"description":"Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 7 investigational indications."}
{"id":"CHEMBL608533","canonicalSmiles":"CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4","inchiKey":"BMGQWWVMWDBQGC-IIFHNQTCSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"MIDOSTAURIN","yearOfFirstApproval":2017,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Rydapt"],"synonyms":["CGP 41251","CGP-41251","Midostaurin","NSC-656576","NVP-PKC412","PKC 412","PKC-412","Pkc-412"],"crossReferences":{"DailyMed":["midostaurin"],"PubChem":["124950161"],"Wikipedia":["Midostaurin"],"drugbank":["DB06595"],"chEBI":["63452"]},"linkedTargets":{"rows":["ENSG00000128052","ENSG00000154229","ENSG00000065675","ENSG00000126583","ENSG00000171132","ENSG00000157404","ENSG00000166501","ENSG00000163558","ENSG00000113721","ENSG00000115825","ENSG00000134853","ENSG00000067606","ENSG00000163932","ENSG00000027075","ENSG00000122025","ENSG00000184304"],"count":16},"linkedDiseases":{"rows":["EFO_0000198","EFO_0000616","EFO_0000565","EFO_0000220","MONDO_0019457","EFO_0007359","EFO_0001421","EFO_1000657","MONDO_0016586","EFO_0000222","EFO_1000131","EFO_0009001","EFO_1002001"],"count":13},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 5 approved and 6 investigational indications."}
{"id":"CHEMBL626","canonicalSmiles":"CN(C/C=C/c1ccccc1)Cc1cccc2ccccc12","inchiKey":"OZGNYLLQHRPOBR-DHZHZOJOSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"NAFTIFINE","yearOfFirstApproval":1988,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["AW-105-843","Naft-500","Naftifine"],"crossReferences":{"DailyMed":["naftifine%20hydrochloride"],"Wikipedia":["Naftifine"],"chEBI":["7451"]},"childChemblIds":["CHEMBL1200493"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1988 and is indicated for tinea pedis and tinea and has 1 investigational indication."}
{"id":"CHEMBL646","canonicalSmiles":"Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1Cl)=NC2","inchiKey":"JOFWLTCLBGQGBO-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"TRIAZOLAM","yearOfFirstApproval":1978,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":true,"isApproved":true,"withdrawnNotice":{"countries":["United Kingdom"," France"," Netherlands"," Finland"," Argentina"],"classes":["Neurotoxicity"," Psychiatric toxicity"],"year":1992},"tradeNames":["Halcion","Kention","Triazolam"],"synonyms":["N05CD05","Triazolam","Triazolam civ","U-33,030","U-33030"],"crossReferences":{"DailyMed":["triazolam"],"PubChem":["144206170","50113071"],"TG-GATEs":["120"],"Wikipedia":["Triazolam"],"drugbank":["DB00897"],"chEBI":["9674"]},"linkedTargets":{"rows":["ENSG00000182256","ENSG00000022355","ENSG00000011677","ENSG00000163285","ENSG00000151834","ENSG00000113327","ENSG00000186297"],"count":7},"linkedDiseases":{"rows":["MONDO_0005090","EFO_0003890","MONDO_0002050","HP_0000726","EFO_0005230","EFO_0004698"],"count":6},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1978 and is indicated for insomnia and has 5 investigational indications. It was withdrawn in United Kingdom,  France,  Netherlands,  Finland and  Argentina initially in 1992 due to Neurotoxicity and  Psychiatric toxicity. This drug has a black box warning from the FDA."}
{"id":"CHEMBL652","canonicalSmiles":"O=C(NCC1CCCCN1)c1cc(OCC(F)(F)F)ccc1OCC(F)(F)F","inchiKey":"DJBNUMBKLMJRSA-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"FLECAINIDE","yearOfFirstApproval":1985,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Flecainide","NSC-719273","THN-102 COMPONENT FLECAINIDE"],"crossReferences":{"DailyMed":["flecainide%20acetate"],"PubChem":["104171159","124880129","144203702","170464874","26752195"],"Wikipedia":["Flecainide"],"drugbank":["DB01195"],"chEBI":["75984"]},"childChemblIds":["CHEMBL4591096","CHEMBL1200822"],"linkedTargets":{"rows":["ENSG00000183873"],"count":1},"linkedDiseases":{"rows":["Orphanet_247","EFO_0000275","EFO_0004269","EFO_0005306","HP_0004308","EFO_0003843"],"count":6},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and is indicated for ventricular arrhythmia and cardiac arrhythmia and has 3 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL67","canonicalSmiles":"COc1ccc(/C=C\\c2cc(OC)c(OC)c(OC)c2)cc1O","inchiKey":"HVXBOLULGPECHP-WAYWQWQTSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"COMBRETASTATIN A4","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Combrestatin A4","NSC-613729"],"crossReferences":{"PubChem":["486760"],"Wikipedia":["Combretastatin_A-4"],"drugbank":["DB14680"]},"childChemblIds":["CHEMBL2028467","CHEMBL43582","CHEMBL41041"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL673","canonicalSmiles":"C#CCN(C)Cc1ccccc1","inchiKey":"DPWPWRLQFGFJFI-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PARGYLINE","yearOfFirstApproval":1982,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Eutonyl","Eutron","Pargyline"],"crossReferences":{"PubChem":["11111668","11111669","90340843"],"Wikipedia":["Pargyline"],"drugbank":["DB01626"],"chEBI":["7930"]},"childChemblIds":["CHEMBL1200425"],"linkedTargets":{"rows":["ENSG00000189221","ENSG00000069535"],"count":2},"linkedDiseases":{"rows":["EFO_0000537"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and is indicated for hypertension."}
{"id":"CHEMBL75680","canonicalSmiles":"CCCCc1c(-c2ccc(O)cc2)[nH]c2nccnc12","inchiKey":"PRIGRJPRGZCFAS-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ALOISINE A","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Aloisine A"],"crossReferences":{"drugbank":["DB07364"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL768","canonicalSmiles":"COC(=O)CCc1ccc(OCC(O)CNC(C)C)cc1","inchiKey":"AQNDDEOPVVGCPG-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ESMOLOL","yearOfFirstApproval":1986,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":true,"isApproved":true,"withdrawnNotice":{"countries":["United States"],"year":2007},"tradeNames":[],"synonyms":["ASL-8052-001","Esmolol"],"crossReferences":{"DailyMed":["esmolol%20hydrochloride"],"Wikipedia":["Esmolol"],"drugbank":["DB00187"],"chEBI":["88206"]},"childChemblIds":["CHEMBL1201115"],"linkedTargets":{"rows":["ENSG00000169252","ENSG00000043591"],"count":2},"linkedDiseases":{"rows":["HP_0000360","EFO_0004210","EFO_0006834","EFO_0007486","EFO_0000275","EFO_0002687","EFO_0001645","EFO_0000319","EFO_0000538","EFO_0003843","EFO_0000537","HP_0100543","EFO_1001459","EFO_0003870","HP_0000138","HP_0031273","EFO_0003833","EFO_0005672","EFO_0005251","EFO_1002005"],"count":20},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and is indicated for cardiovascular disease and hypertension and has 12 investigational indications. It was withdrawn in United States  in 2007."}
{"id":"CHEMBL86715","canonicalSmiles":"OC(CCN1CCCC1)(c1ccccc1)C1CCCCC1","inchiKey":"WYDUSKDSKCASEF-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PROCYCLIDINE","yearOfFirstApproval":1955,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Elorine","Kemadrine","Lergine","NSC-169103","Procyclidine","Tricoloid","Vagosin"],"crossReferences":{"drugbank":["DB00387"],"chEBI":["8448"]},"childChemblIds":["CHEMBL1761"],"linkedTargets":{"rows":["ENSG00000168539"],"count":1},"linkedDiseases":{"rows":["MONDO_0005180"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1955 and is indicated for parkinson disease."}
{"id":"CHEMBL92915","canonicalSmiles":"CC(CC(C(N)=O)(c1ccccc1)c1ccccc1)N(C)C","inchiKey":"NARHAGIVSFTMIG-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"AMINOPENTAMIDE SULFATE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Aminopentamide","Aminopentamide acid sulfate, dl-","Aminopentamide hydrogen sulfate","Aminopentamide sulfate","Aminopentamide sulphate","BL-139","Centrine","Dimevamide","Dimevamide sulfate","NSC-759162"],"crossReferences":{"drugbank":["DB15597"]},"childChemblIds":["CHEMBL3561133"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL95431","canonicalSmiles":"NC(=O)c1nnn(Cc2cc(Cl)c(C(=O)c3ccc(Cl)cc3)c(Cl)c2)c1N","inchiKey":"WNRZHQBJSXRYJK-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CARBOXYAMIDOTRIAZOLE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Carboxyamidotriazole","L 651582","NSC-609974"],"crossReferences":{"PubChem":["124753387","174006266","4254373","485747","50109733"],"drugbank":["DB11960"]},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications."}
{"id":"CHEMBL96852","canonicalSmiles":"COc1nccnc1C(C)C","inchiKey":"NTOPKICPEQUPPH-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL96852","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB01760"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL973","canonicalSmiles":"C/C(O)=C(\\C#N)C(=O)Nc1ccc(C(F)(F)F)cc1","inchiKey":"UTNUDOFZCWSZMS-YFHOEESVSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"TERIFLUNOMIDE","yearOfFirstApproval":2012,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Aubagio"],"synonyms":["A77 1726","HMR-1726","HMR1726","Leflunomide related compound b","Leflunomide related compound b rs","Teriflunomide"],"crossReferences":{"DailyMed":["teriflunomide"],"Wikipedia":["Teriflunomide"],"drugbank":["DB08880"],"chEBI":["68540"]},"linkedTargets":{"rows":["ENSG00000102967"],"count":1},"linkedDiseases":{"rows":["EFO_0001060","EFO_0003086","MONDO_0005301","EFO_0000540","EFO_0007527"],"count":5},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and is indicated for immune system disease and multiple sclerosis and has 3 investigational indications. This drug has a black box warning from the FDA."}
